Bausch Health Companies and Ortho Dermatologics announced statistically significant topline results from a second pivotal Phase 3 clinical trial evaluating the investigational medicine IDP-126, a combination retinoid, anti-bacterial and antibiotic topical to treat acne vulgaris in patients 9 years of age and older.

The U.S. Food and Drug Administration approved Italy-based Cassiopea SpA’s acne treatment Winlevi (clascoterone cream 1%).

Bausch Health Companies Inc. and the company’s dermatology business Ortho Dermatologics announced that the U.S. Food and Drug Administration accepted the New Drug Application for IDP-123 (tazarotene 0.045%) Lotion, with a PDUFA action date of Dec. 22, 2019.

The U.S. FDA accepted for review Foamix Pharmaceuticals Ltd.’s New Drug Application (NDA) for FMX101 for treating inflammatory lesions of non-nodular moderate-to-severe acne vulgaris.

The U.S. FDA approved Ortho Dermatologics’ NDA for Altreno (tretinoin 0.05%) lotion, indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.